Prediction Models for Diagnosis and Prognosis of Severe COVID-19

NCT ID: NCT04525287

Last Updated: 2021-08-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

617 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-02-20

Study Completion Date

2020-08-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinical observation has found that COVID-19 patients often present inconsistency of clinical features, nucleic acid of the SARS-CoV-2 and imaging findings, which brings challenges to the management of patients.The quantitative assessment of patients' pulmonary lesions of chest CT, combined with the basic information, epidemiological history, clinical symptoms, basic diseases and other information of patients, will quickly establish a reliable prediction model for the severe COVID-19. This model will greatly contribute to the effective diagnosis and treatment of COVID-19.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Research purpose

The research team collected the clinical and chest CT of 1,000 COVID-19 patients from multiple hospitals. We plan to use these data to explore the imaging features of the COVID-19 and develop a convenient, easy-to-use, highly reliable imaging AI model for detecting and predicting the severe COVID-19. The model is used for imaging evaluation of COVID-19 patients, in order to achieve the purpose of early diagnosis, reasonable management of patients and prediction of severe COVID-19.
2. Research design and methods:

This research is a retrospective study. The project research period have 6 months. Start time: the date of ethics approval.

End time: August 20, 2020.

2.1 Establish an AI model for the detection of COVID-19 chest CT lesions Based on existing models and data, rapid detection of lesions on the chest high-resolution CT (HRCT) images of COVID-19, identification of the character of the lesions including the volume of the lesions.

2.1.1 Research data COVID-19 Group: 1,000 cases of COVID-19 patients who were tested positive for nucleic acid of the SARS-CoV-2 in more than ten designated hospitals within and outside Zhejiang Province. all underwent chest HRCT examination and relatively complete clinical and laboratory data.

Control group: patients with other viral and bacterial pneumonia. A collection of 1000 patients with other types of pneumonia in multiple centers, all underwent chest HRCT examination and relatively complete clinical data.

2.1.2 Research methods

1. Lesion detection, segmentation and quantification. Based on the artificial intelligence analysis function developed by Yitu Technology, the patient's chest CT image data is analyzed, including: a. Detecting lung lesions; b. Quantitative and radiomics analysis of key imaging features such as the shape, extent, and density of the lesions, and accurately calculating the cumulative pneumonia burden of the disease; c. For focal lesions, diffuse lesions, quantitative analysis of the severity of various pneumonia diseases involving the entire lung.
2. Based on the above-mentioned lesion segmentation detection results, analyze the characteristic manifestations of the COVID-19. Observe the differences in the number, shape, range, density, and radiomics characteristics of lung lesions in patients with COVID-19 and other pneumonia, and quantify their unique lung characteristics. Compare and analyze the correlation of lung characteristics with clinical symptoms and guideline classification characteristics, and clarify the value of quantitative mathematical characteristics in auxiliary diagnosis classification.

2.2 Establish an AI model for predicting severe COVID-19 Establish a reliable AI model for predicting severe COVID-19 through chest CT imaging data of the patient, basic patient information, epidemiological history, clinical symptoms, and underlying diseases. It is planned to establish a severe COVID-19 risk assessment system that can not only assist doctors in the critical evaluation of patients in hospital, but also warn the severe risk of patients in home isolation. The system will include simple and accurate models. The former only uses patient images, basic demographic characteristics, symptoms and other easy-to-collect information. This model may be used in Wuhan City that has basic data for mild cases but has no treatment conditions. Allow them to be isolated at home or other patients without medical resources, and early warning of the risk of severe transformation in the hospital system for preliminary testing, so as to facilitate subsequent patient management and treatment. The complex model will incorporate more complex and detailed information, such as multiple images of patients and blood test data, to establish a more accurate predictive model, which can be used to provide reference for the diagnosis and treatment strategies of patients in the hospital, and can prompt more COVID-19 Factors related to pneumonia.

2.2.1 Research object 1,000 patients with mild cases of novel coronavirus pneumonia were diagnosed, and were divided into severe group and non-severe group based on subsequent clinical outcomes.

Definition of mild illness: The patient only showed symptoms such as fever and respiratory tract in general, and no severe symptoms occurred during the visit and follow-up.

Definition of severe illness: Patients who have one of the following conditions during treatment: 1. Respiratory distress, RR≥30 beats/min; 2. In resting state, mean oxygen saturation≤93%; 3. Arterial oxygen partial pressure ( PaO2)/Inhalation Oxygen Concentration (FiO2) ≤300mmHg (1mmHg=0.133kPa); 4. Respiratory failure occurs and mechanical ventilation is required; 5. Shock occurs; 6. ICU monitoring and treatment is required for combined other organ failure.

2.2.2 Research methods This study uses artificial intelligence technology to predict the severity of patients with mild illness. The data required for its modeling comes from multiple sources: (1) Using radiomics analysis technology, extract the CT image of the patient including the chest CT value, shape and size of the lesion high-dimensional imaging radiomics features such as texture and wavelet features to obtain more accurate and comprehensive image data information. Yitu's existing imaging raidomics feature extraction tool can extract up to 5,900 CT image features to make lung state more accurate assessment and prediction It becomes possible; (2) Collecting information on the subjective evaluation of CT image signs by imaging doctors, as well as multi-dimensional information such as basic patient information, disease history, laboratory test results, and clinical symptoms; (3) Based on the developed chest CT image analysis Function to extract quantitative parameters such as pneumonia load index, patch semi-quantitative information and so on using deep learning technology.

The total collected data set is divided into training set and internal verification set. Firstly, the information is analyzed by traditional medicine and multi-dimensional AI algorithm, comprehensively and quantitatively analyze whether the data column is included in the prediction model and the weight in the model, and look for strongly related factors. Try to use machine learning, deep learning and other AI algorithms to establish a risk prediction model for severe COVID-19. And the results output the probability of the patient's severity, and classify the risk of the patient's severity. Evaluate the model's ability to identify high-risk and low-risk patients with indicators such as sensitivity, specificity, and preliminarily verify the stability of the model.

2.2.3 Clinical application verification After the prediction model is established, the prediction model will continue to be used in the subsequent multi-center collection of supplementary clinical patient data, use patient follow-up data to verify its sensitivity and specificity, and continuously incorporate the newly collected data into the model training set to continuously improve the prediction model. Improve the application efficiency of risk assessment models. In the end, it will reduce the conversion rate of severe patients, reduce the management pressure of mild patients, and better assist doctors in clinical diagnosis and treatment decision-making and patient management.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronavirus Infection COVID19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Severe COVID-19

Patients who have one of the following conditions during treatment: 1. Respiratory distress, RR≥30 beats/min; 2. In resting state, mean oxygen saturation≤93%; 3. Arterial oxygen partial pressure ( PaO2)/Inhalation Oxygen Concentration (FiO2) ≤300mmHg (1mmHg=0.133kPa); 4. Respiratory failure occurs and mechanical ventilation is required; 5. Shock occurs; 6. ICU monitoring and treatment is required for combined other organ failure.

No interventions assigned to this group

Mild COVID-19

The patient only showed symptoms such as fever and respiratory tract in general, and no severe symptoms occurred during the visit and follow-up.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient was tested positive for nucleic acid of the SARS-CoV-2

Exclusion Criteria

* none
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of radiology, The Second People's Hospital, Fuyang, Anhui, China

Fuyang, Zhejiang, China

Site Status

2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

Hangzhou, Zhejiang, China

Site Status

Department of Radiology, The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China

Jiaxing, Zhejiang, China

Site Status

Department of Radiology, Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, China

Taizhou, Zhejiang, China

Site Status

Department of Radiology, Ruian People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Ruian, Zhejiang, China

Wenzhou, Zhejiang, China

Site Status

Department of Radiology, Yueqing People's Hospital, Yueqing, Wenzhou, Zhejiang, China

Wenzhou, Zhejiang, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-12020001231

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.